Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

17.03
+0.02000.12%
Post-market: 17.030.00000.00%16:10 EDT
Volume:332.38K
Turnover:5.66M
Market Cap:882.64M
PE:16.30
High:17.07
Open:17.02
Low:17.00
Close:17.01
52wk High:21.03
52wk Low:13.08
Shares:51.83M
Float Shares:25.78M
Volume Ratio:0.89
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.05
EPS(LYR):2.06
ROE:20.91%
ROA:1.33%
PB:3.05
PE(LYR):8.27

Loading ...

Jan 05, 2024

Major Issues Report

Form 8-K - Current report
Dec 28, 2023

Major Issues Report

Form 8-K - Current report
Dec 22, 2023

Major Issues Report

Form 8-K - Current report
Nov 15, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 10, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 08, 2023

Major Issues Report

Form 8-K - Current report
Oct 30, 2023

Major Issues Report

Form 8-K - Current report
Oct 17, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 15, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 12, 2023

Major Issues Report

Form 8-K - Current report
Aug 15, 2023

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Aug 11, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 09, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2023

Major Issues Report

Form 8-K - Current report
Jul 14, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 10, 2023

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jun 14, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 10, 2023

Major Issues Report

Form 8-K - Current report
Jun 08, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 18, 2023

[Rev.]Quaterly Report

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]